Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD).
T REATMENT EFFECTIVENESS OF major depressive disorder (MDD) depends on early and accurate diagnostic efficacy. 1 Unlike other medical conditions, there is presently no practical and established diagnostic method for the objective assessment of MDD severity, subtypes, and treatmentresponse monitoring. 2 Routine medical and behavioral examinations based on interviews conducted by mental health specialists are the only available tools for diagnosing MDD. However, the reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) is still between 0.7 and 1.0. 3 Moreover, the SCID-I is not amenable for clinical utility in the primary care setting, as it requires extensively trained doctors, longer time to administer, and interviewbased psychometric examination. Thus, the need for the development of an objective tool for MDD is long overdue and warranted.
Studies of psychoneuroimmunology have shown that psychiatric diseases, especially MDD, correlate with reduced peripheral immunity, and thus suggest the possibility of the presence of biomarker candidates for MDD. [4] [5] [6] The purpose of the present study was to examine plasma phosphoethanolamine (PEA) levels in MDD patients and other mental disorders, and to evaluate the possibility of using plasma PEA measurement as a candidate metabolite biomarker of MDD.
As an advancement towards protein-based biomarker research, a large cohort study of 1589 participants from the Netherlands Study of Depression and Anxiety suggested a correlation between MDD and certain analytes in relation to a diverse cell-cell communication, signal transduction, immune response, and protein metabolism. 7 Moreover, a series of reports has also shown evidence of reproducibly robust sets of MDD biomarkers; however, the complications associated with running the assays renders them user-unfriendly. 8 Furthermore, using a combinatorial mathematical approach, Papakostas et al. reported that serum levels of nine biomarkers, sex, and body mass index (BMI) could yield an MDD score for diagnostic or predictive utility. 9 In studies investigating non-protein biomarkers, methylation profiles of CpG-Islands (CpGI) of the brainderived neurotropic factor (BDNF) gene identified patients with MDD, 10 with baseline levels of nine transcriptional markers differing significantly between MDD and control subjects. 11 In metabolomics studies, the abnormally low cerebrospinal fluid (CSF) ethanolamine levels observed in the patients with MDD were strongly associated with the severity of depression and somatic anxiety symptoms. 12 Recently, five plasma metabolites (3-hydroxybutyrate, betaine, citrate, creatinine, and γ-aminobutyric acid) were reported to be associated with severity of depression. 13 An effective MDD biomarker must therefore be able to clearly differentiate between anxiety disorder and MDD. Any biomarker that detects anxiety and anxiety disorder as MDD implies that nearly all cases seen by a clinician would be categorized as MDD, resulting in inappropriate therapeutic clinical decision-making. Extra effort by clinicians is required to extract the exact symptoms of MDD as identified by the SCID-I method. As it stands, five of the other interview-based MDD diagnostic criteria resemble generalized anxiety disorder (GAD). Furthermore, the interview-based Hamilton Rating Scale for Depression and the MontgomeryÅsberg Depression Rating Scale are equally limited in their ability to clearly discern MDD from GAD. 3, [14] [15] [16] This study involved three different cohorts at psychiatric offices in order to overcome the drawbacks of candidate biomarkers identified by omics technologies, including those that usually use: (i) too many variables; (ii) ambiguous evidence of reproducibility; (iii) the use of only relative ratios of variables without absolute concentrations; and (iv) unrealistically low throughput due to high assay costs or data-acquisition complexities. Plasma metabolome profiles of MDD and other mental disorders were analyzed in order to identify potential MDD biomarker candidates. Among the candidates identified, PEA was selected for further analysis. In the preliminary and checking cohort studies, the discriminative potential of plasma PEA concentrations was tested using ion-chromatography fluorescence detector (IC-FLD) to determine the reproducibility and utility of PEA for distinguishing MDD from non-MDD subjects.
METHODS

Human subjects
In the exploratory cohort study, patients with MDD and mentally healthy volunteers were recruited from the National Center of Neurology and Psychiatry Japan (NCNP) between 2007 and 2009. All patients were outpatients. For recruitment of healthy volunteers, this study was advertised through the City of Kodaira, Tokyo. Written informed consent was given by each subject for participation in the study under the approval of the NCNP Institutional Ethics Committee. Each patient was diagnosed using the DSM-IV-TR, and the diagnosis was confirmed using the SCID-I. The Center of Epidemiologic Studies Depression Scale 17 and the State-Trait Anxiety Inventory Scale 18 were also administered to the subjects. In the preliminary and checking cohorts, both cases and controls were selected from nonmedicated outpatients who had visited the Kawamura Clinic for General Practice (KCGP). Subjects were recruited between 2013 and 2014 and provided with written informed consent for participation in the study under the approval of the KCGP Institutional Ethics Committee. The same diagnostic procedure was used at both the NCNP and KCGP. Subjects were also administered three lie scale questions, and those who did not answer 'no' to all three were eliminated from the study. The control group included patients with non-MDD disorders other than those listed in the exclusion criteria for MDD. In other words, the patients who met the B, C, and E criteria of major depressive episode, along with those categorized as B and C in MDD of 296.2× in the DSM-IV were all eliminated from the control 19 (preliminary cohort: n = 43 non-MDD vs n = 34 MDD; checking cohort: n = 13 non-MDD vs n = 10 MDD).
Blood sampling
Subjects were instructed not to consume alcohol the day before the test and to avoid meals at least 2 h prior to the test. Peripheral blood samples were collected in 5-7-mL EDTA-2Na vacuum tubes (Terumo, Tokyo, Japan) with clinical data obtained at the same time. In the exploratory cohort, blood sampling of all the subjects was done at 11:00 am to reduce the effects of circadian rhythms. In the subsequent two cohorts, blood sampling time was not controlled for. Within 1 h of blood collection, plasma was separated out by centrifugation, at 1000 g for 10 min and 800 g for 15 min at room temperature with swing-type and angled-type centrifugal rotors, respectively (see Fig. S1 ). A 1-mL aliquot of plasma was immediately frozen in liquid nitrogen. The stored samples were transported packaged on dry ice from the hospitals in Tokyo, Japan to Human Metabolome Technologies Inc. (HMT) laboratories in Yamagata, Japan.
Metabolomic analysis
Metabolite extraction from plasma samples, metabolome analysis using a capillary-electrophoresis time-offlight mass spectrometer (CE-TOFMS), and data processing were all performed as described previously. 
Targeted analysis of PEA by IC-FLD
When analyzing samples containing such concentration as around the detection limit of MS, it is generally suggested that the probability of not being detected is 50%. [21] [22] [23] Since quantification of PEA by CE-TOFMS is sometimes lower than the determination limitation (signal-to-noise ratio is less than 10), 24 quantitativeness cannot be maintained even when PEA concentration in plasma is about 2 μM (Fig. S3 ). Therefore, we had to seek a method to quantify PEA accurately by a quantitative method other than mass spectrometers. As amino acid analyzers cannot measure plasma PEA concentrations, and in order to eliminate defects (iii and iv) in -omics studies, a new IC-FLD was developed to accurately quantify plasma PEA values more readily than CE-MS (Appendix S1 and Fig. S2 ). Relative SD to measure plasma PEA and spiked PEA recovery rate were approximately 3% and 100%, respectively (Fig. S2) , indicating that the IC-FLD method provides accurate determination of plasma PEA.
Statistical methods
Metabolomics data were analyzed with R (version 2.11; www.r-project.org). Candidate metabolite biomarkers (mBM) were screened by comparing relative levels of metabolites between MDD and controls using the Wilcoxon rank sum test. P-values were corrected for multiple hypotheses testing with the Bonferroni method, and Q-values were also calculated from the same P-value list.
To calculate the appropriate preliminary and checking cohort sizes, Medcalc v.16-2 (https://www. medcalc.org/) was used. The negative-to-positive (N/P) ratio was set at 1.25 because the actual N/P ratio in the KCGP cohort was 1.25 (data not shown). Participant demographics and clinical characteristics were compared using the Wilcoxon rank sum test and the Kruskal-Wallis one-way analysis of variance (ANOVA) and χ 2 -tests, accordingly. The Steel-Dwass multiple comparisons method was performed following ANOVA. Analysis of covariance (ANCOVA) was further performed to verify covariate effect of habitual alcohol intake in the relations between PEA values and SCID-I-derived MDD symptoms.
RESULTS
Metabolome analysis to find mBM Table 1 shows the demographic data of the exploratory cohort. Sample size includes the maximum number of eligible subjects available during the study period. Metabolomic profiles of the 65 plasma samples were analyzed using CE-TOFMS, resulting in 538 peak signals. Using the m/z and MT values of the metabolome library, 195 signals were annotated as specific metabolites. Out of the 195 specific metabolites, 138 were detected in most samples (Table S1) , with all the residual peaks listed in Table S2 . All statistical analyses were performed by Asterisks indicate degree of significance in difference between MDD and healthy controls: * 0.01 < P < 0.05; ** 0.001 < P < 0.01; *** P < 0.001. CES-D, Center of Epidemiologic Studies Depression Scale; MDD, major depressive disorder; STAI, State-Trait Anxiety Inventory.
comparing the MDD and control groups. Q-value analysis identified 49 of the 138 annotated metabolites and 42 of the 343 unannotated peaks as significantly different between MDD and controls. Almost all the significant peaks were substantially reduced in the MDD group. Following Bonferroni correction, 23 peaks overall were significantly lower in the MDD group, and out of these, 15 peaks were annotated metabolites (Table 2 ).
Metabolomics identification of novel mBM
The areas under the receiver-operator curve (AUC) for PEA and taurine were 0.87 (P < 0.0001) and 0.86 (P < 0.0001), respectively. These two metabolites were the strongest biomarker candidates. Taurine is synthesized in the liver and widely distributed in most other organs. Additionally, plenty of taurine is contained in several foods. Taurine was therefore eliminated in order to overcome omics research defect (i). Finally, PEA was selected as the most promising mBM candidate for the detection of MDD.
Assessment of plasma PEA as an MDD candidate biomarker
In order to prove whether the test might be practical in the context of primary-care psychiatry clinics, it was necessary to compare PEA concentrations between MDD and patients with non-MDD disorders.
In order to see if the blood test had moderate accuracy, an appropriate sample size of the preliminary cohort was calculated to assess the practical use of PEA as an MDD mBM, assuming α = 0.05/2, β = 0.20, N/P ratio = 1.25, and the AUC was approximately 0.70. The estimated sample size needed for the study was 34 MDD and 43 control subjects. The demographic data of this cohort are shown in Table 3 . The AUC, sensitivity, and specificity of PEA in the preliminary cohort were sufficiently high (0.92 AE 0.04, 88.1%, and 88.6%, respectively; Fig. 1a) , and support the conclusion that plasma levels of PEA less than the absolute threshold of 1.46 μM strongly indicate the presence of MDD.
To confirm the results, we calculated the sample size of the checking cohort, assuming that the AUC was equal to 0.85 based on the lower limit of the 95% confidence interval for the AUC value in the preliminary cohort. An adequate sample size was estimated to be 10 MDD and 13 control subjects. Table 3 shows the demographic data of the checking cohort. The AUC sensitivity, and specificity of PEA in the checking cohort were sufficiently high (0.89 AE 0.08, 84.6%, and 100%, respectively; Fig. 1b) , and the reproducibility of the results Other comorbid disorders found in the preliminary cohort were borderline personality disorder (n = 1), attention deficit hyperactivity disorder (n = 1), insomnia (n = 2), phobia (n = 1), pervasive developmental disorder (n = 1), and bulimia nervosa (n = 1) for the non-MDD subjects; and somatoform disorders (n = 1) and dissociative disorder (n = 1) for the MDD subjects. In the checking cohort, cyclothymic disorder (n = 1) was found for a non-MDD subject. One and two healthy subjects were included in the preliminary and checking cohorts, respectively. The preliminary cohort also included the previous MDD patients (partially remitted, n = 2; completely remitted, n = 2). The numbers of the subjects are indicated in parentheses. CES-D, Center of Epidemiologic Studies Depression Scale; MDD, major depressive disorder; PEA, phosphoethanolamine; STAI, State-Trait Anxiety Inventory. obtained in the preliminary cohort was confirmed. These results demonstrate that the plasma PEA as a candidate of MDD biomarker, if further confirmed, could have practical applications in the primary care settings. Furthermore, as shown in Table 3 , and despite the sample size, PEA appeared to be independent of GAD. We compared the plasma PEA levels of patients with MDD without any comorbidity (n = 20), MDD with GAD (n = 21), and GAD (n = 11). The mean PEA levels of each group were 1.21 AE 0.16 μM, 1.29 AE 0.14 μM, and 1.83 AE 0.60 μM, respectively. ANOVA showed significant differences among the groups (P < 0.0001, F = 15.8).
Using the Scheffe post-hoc test, significant differences were observed between the comparison of pure MDD and GAD (P < 0.001), and the comparison between MDD with GAD and GAD (P < 0.001). No significant differences were found in the comparison between MDD and MDD with GAD (P > 0.05). ANCOVA indicated that MDD had significant correlation with plasma PEA levels (F = 35.9, P < 0.0001) and GAD did not (F = 0.03, P = 0.87). No significant interaction between MDD and GAD was found to affect plasma PEA values (F = 0.11, P = 0.74).
MDD symptoms correlate with low plasma PEA levels
Among the demographic variables listed in Table 3 , only habitual alcohol intake was significantly related to low PEA values (t-test, P < 0.05). The mean PEA concentrations in non-drinkers (n = 40) and drinkers (n = 60) were 1.72 AE 0.65 μM and 1.50 AE 0.37 μM, respectively. Habitual alcohol intake was therefore used as a covariate in the ANCOVA for the relations between PEA values and SCID-I-derived MDD symptoms (Fig. 1c) . Depressed mood (A1), diminished interest or pleasure (A2), psychomotor change (A9), psychomotor retardation (A10), and current episode of MDD (A24) were significantly correlated with reduced plasma PEA levels after Bonferroni correction. The Pearson correlation coefficient was −0.391 (n = 100, P < 0.001) between plasma PEA concentrations and the sum of the series of criterion items for diagnosing MDD. In other words, the severity of MDD negatively correlates with PEA. The raw data are available upon request.
DISCUSSION
The present study found significant differences in plasma PEA levels between MDD patients and controls. Using the metabolomics approach, we identified 23 metabolites as potential candidate biomarkers for MDD, and we selected PEA for further analysis. Among the MDD symptoms studied, depressed mood (A1), diminished interest or loss of pleasure (A2), and psychomotor retardation (A10) were particularly well correlated with plasma PEA levels. To our knowledge, this is the first study to report on plasma PEA as a candidate biomarker for MDD.
Moreover, a recent study also reported that psychomotor retardation is a central feature of MDD, along with motor and cognitive impairment. 25 Additionally, a meta-analysis study by van Loo et al., used latent factor analysis, and reported the identification of a factor that clarified variances in the MDD symptoms of depressed mood and loss of interest (11 of 13 analyses), usually accompanied by psychomotor retardation or fatigue (eight of 11 analyses). 26 These studies complement the present study.
The contribution of various metabolic pathways to PEA generation has not been determined yet. Further studies will be required to clarify the mechanisms behind the low plasma PEA in MDD patients.
As a phosphomonoester metabolite of phospholipids, PEA is both a precursor and a byproduct of phospholipid biosynthesis and breakdown, respectively (Fig. 2) . As a precursor of phosphatidylethanolamine (PE), elevated PEA level is known to reflect brain phospholipid turnover, an indicator of neural membrane synthesis and signal transduction. 27 Interestingly, γ-aminobutyric acid binding and uptake are also modulated by altered membrane levels of PE. 28, 29 As a precursor for PE, PEA has been suggested to play a key role in myelination, as significantly high levels of PEA have been reported in purified myelin 30, 31 and both PEA and taurine have been implicated in important cellular functions, including osmoregulation, neuromodulation, and membrane stability. 32 As PEA lies at a vantage point where various phospholipid biosynthetic pathways converge, its cellular, tissue, and organ levels depend a great deal on the relative contributions of the respective pathways, as PEA depends on its on-demand temporal physiological need either as a precursor or metabolite of phospholipids. Myelin PEA is essential for PEA cytidylyltransferase to catalyze the formation of cytidine-5'-diphosphate ethanolamine for the subsequent completion of brain . Both MDD and non-MDD subjects were categorized into two groups based on the coding '1 or 2' and '3.' Statistical significances in the difference of the mean PEA levels between the groups are indicated by asterisks: * 0.01 < P < 0.05; *** P < 0.001. PE biosynthesis, which is important for neural membrane integrity and signal transduction. 33, 34 Another interesting finding is an interrelationship between extracellular taurine and PEA. 35 Taurine has effects of membrane stabilization in CNS. Depletion of taurine pool in the hippocampus results in extracellular increase in taurine and PEA. The mechanisms are still unknown; however, the same coupling phenomenon was observed in this paper. On the relation between other amino acids and MDD, there are a few previous reports in the literature. In this study, besides PEA, taurine and lysine along with other amino acids were all decreased in MDD patients. While Mitani et al. saw a significant increase in taurine among depression patients, in the current study, taurine was significantly decreased in our MDD patients compared to controls. 36 Furthermore, contrary to Mitani et al., the amino acids detected in our study all negatively correlated with depression score. Additionally, in the study by Steffens et al., the authors found increased levels of various amino acids and dicarboxylic fatty acids among heart failure patients with MDD compared with non-MDD heart failure patients. 37 Amino acids like aspartate, glutamate, phenylalanine, and serine were all significantly increased in MDD heart failure patients compared to non-MDD heart failure controls. 34 Their subjects were all heart failure patients, whereas our participants were all clinically diagnosed MDD and non-MDD controls. Both Mitani et al. and the present study focused on non-disease MDD cases and controls. Meanwhile, Woo et al. reported that α-aminobutyric acid differentiated MDD patients according to their response to a therapeutic regimen of selective serotonin reuptake inhibitors. 38 However, their goal was different from that of the present study in that it was not aimed at early detection of MDD, but rather at MDD therapeutic response, which lies in a timeframe later than our targeted point of reference in the MDD sequelae. Unlike the studies discussed above, our study was designed to identify pathologically relevant bloodplasma-based early discriminative biomarkers candidates that could be used to screen for MDD before full-blown complications set in.
Finally, Xu et al. reported that tryptophan, glutamine, and cysteine delineated treatment-naïve MDD cases from healthy controls. 39 They found no significant difference in PEA levels; however, consistent with our results, methionine, phenylalanine, and lysine were all decreased in their MDD patients. Disparities between these studies and the present study could not be overlooked. Besides differences in study goals and design, technical variations in sample handling, centrifugation, and time differences between blood sampling and processing stringency may underlie the discrepancies. PEA, which was featured in this study, is hardly analyzed by conventional analytical methods (e.g., liquid chromatography) due to: (i) unexpected binding of PEA to metallic materials used in the systems; (ii) difficulty in separation by metabolomic methods; and (iii) problems with the detectors used in conventional studies. 38, 39 We conclude that the previous studies and ours may therefore not be fully comparable as a result of these clear differences; however, IC-FLD is an indispensable method for measuring plasma PEA with sufficient detection power and accuracy.
Limitations
The present study may be limited by sampling bias. The psychiatric clinic from which the preliminary and validation cohorts were recruited is located in the center of Tokyo, hence there is a skew towards wholly urban dwellers. The ratio of women to men might also have been smaller than usual, which might explain the high percentage of melancholia. All participants were Japanese subjects. Nonetheless, the PEA levels of Caucasian expatriates who occasionally visited the clinic also showed ranges of plasma PEA values similar to Japanese subjects (Table S3) .
Another limitation is the relatively small sample size and the types of samples. It was actually impossible to estimate the effects of drugs on the plasma PEA values in the exploratory cohort. Moreover, due to sample size limitation (nine drug-naïve patients to 10 patients medicated with psychoactive drugs), no significant within-group differences could be inferred from medication exposure among the MDD patients (Table 1) . Further studies are warranted to replicate these results and to clarify the effects of many covariates in a larger multicenter cohort.
The third limitation is that only one psychiatrist conducted all psychometric diagnoses throughout the study. Hence the possibility for an interviewer bias cannot be overlooked. Finally, we do not consider our present study to be fully conclusive, or as a final determinant of PEA as an MDD biomarker. The results of the second and third cohorts did not replicate the initial finding of a difference between depression and mentally healthy controls in the exploratory cohort; thus, future replication studies are necessary. In addition, further studies are needed to explain the mechanisms behind the low circulating PEA and MDD symptoms, to fully validate and generalize diagnostic utility.
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Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Figure S1 . Accuracy of ion-chromatographyfluorescence detection (IC-FLD) of phosphoethanolamine (PEA). PEA solution was supplemented with human plasma (including 1.7 μM of PEA) and analyzed by an IC-FLD. Samples were prepared five times for each concentration of PEA. (a) Change in PEA levels within 60 min. No statistically significant difference in mean PEA levels (n = 4) was found. (b) Change in PEA levels within a 24-h period. Statistically significant difference in mean PEA levels of EDTA-treated blood left for 1 h (n = 4) are indicated as asterisk (degree of significance: * 0.01 < P < 0.05; ** 0.001 < P < 0.01). Figure S3 . Correlation between the phosphoethanolamine (PEA) concentrations determined by the capillary-electrophoresis time-of-flight mass spectrometer (CE-TOFMS) and the ion-chromatography fluorescence detector (IC-FLD). Plasma samples obtained from the subjects were analyzed by the two analytical methods simultaneously. (a) List of PEA concentration determined by the two methods with signal-to-noise ratio (S/N). CSA means the internal standard used to normalize the intensity. (b) Relation between the calculated levels by the two methods. Table S1 . Chemically identified metabolites detected in the specimens of the exploratory cohort. Table S2 . Unidentified compounds detected in the specimens of the exploratory cohort. Table S3 . Plasma phosphoethanolamine (PEA) concentration of Caucasians in Gyoukikai Medical Corporation Appendix S1. Methods.
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